This hypothesis helps to explain the correlation of elevated expression of DSC1 with adverse outcomes in mesenchymal CMS4 and CRIS-B patients, representing the most aggressive subtypes of CRC [41]. This evidence concerns the gene DSC1 and colorectal carcinoma.